Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 14th Annual Meeting of the Society of Hematologic Oncology (SOHO) took place on September 9-12, 2026, in Houston, TX, and online. This meeting brought world leaders together to discuss the latest advances and practical clinical applications in hematologic malignancies.

SOHO 2026

The 14th Annual Meeting of the Society of Hematologic Oncology
09–12 September 2026 | Houston, TX

SOHO 2026

The 14th Annual Meeting of the Society of Hematologic Oncology
09–12 September 2026 | Houston, TX
The 14th Annual Meeting of the Society of Hematologic Oncology (SOHO) took place on September 9-12, 2026, in Houston, TX, and online. This meeting brought world leaders together to discuss the latest advances and practical clinical applications in hematologic malignancies.
View all videos

Latest Videos

View all
7:19
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
David Sallman • 1 Oct 2026
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
4:28
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
David Sallman • 1 Oct 2026
1:27
Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
Nitin Jain • 1 Oct 2026

Multiple Myeloma

View all
2:21
Expanding outpatient delivery of bispecific antibodies in multiple myeloma
Hans Lee • 10 Sep 2026
1:37
Emerging therapies after BCMA- and GPRC5D-directed treatment in multiple myeloma
Hans Lee • 10 Sep 2026

Leukemia

View all
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
1:27
Value of genomic assessment in guiding first-line CLL treatment: FISH, IGHV, and TP53 testing
Nitin Jain • 1 Oct 2026

Lymphoma

View all
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Trial Updates

View all
7:19
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
David Sallman • 1 Oct 2026
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals